ADAR1 Capital Management’s Eledon Pharmaceuticals ELDN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.65M Buy
652,812
+5,000
+0.8% +$16.8K 0.07% 156
2026
Q2
$2.55M Sell
647,812
-326,609
-34% -$1.19M 0.12% 132
2026
Q1
$3M Sell
974,421
-847,391
-47% -$2M 0.18% 107
2025
Q4
$2.75M Buy
+1,821,812
New +$4.33M 0.2% 86
2025
Q3
– Sell
-16,900
Closed -$45.8K – 233
2025
Q2
$45.8K Buy
16,900
+300
+2% +$900 0.01% 192
2025
Q1
$56.3K Buy
16,600
+600
+4% +$2.47K 0.01% 179
2024
Q4
$65.9K Buy
+16,000
New +$63.1K 0.01% 190

Other funds holding ELDN

ADAR1 Capital Management's ELDN Position: Q3 2026 in Review

ADAR1 Capital Management increased its Eledon Pharmaceuticals (ELDN) stake by 0.77% in Q3 2026, buying an estimated $16.8K and bringing the position to 652,812 shares worth $1.65M. The position accounts for 0.07% of the portfolio, ranked #156.

ADAR1 Capital Management first reported a position in ELDN in Q4 2024 and has held it in 7 quarters since. The position peaked at $3M in Q1 2026. 155 funds tracked by Wall St. Rank hold ELDN as of Q3 2026.

  • ADAR1 Capital Management held 652,812 shares of Eledon Pharmaceuticals worth $1.65M as of Q3 2026.
  • ADAR1 Capital Management bought 5,000 Eledon Pharmaceuticals shares in Q3 2026, an estimated $16.8K.
  • Eledon Pharmaceuticals made up 0.07% of ADAR1 Capital Management's portfolio in Q3 2026, its #156 holding.
  • ADAR1 Capital Management first reported a position in Eledon Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • ADAR1 Capital Management's Eledon Pharmaceuticals position peaked at $3M in Q1 2026.
  • 155 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q3 2026.

Based on ADAR1 Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.